摘要
目的 总结H_(1)抗组胺药物(AHs)联合治疗过敏性鼻炎(AR)的常见治疗方案,并分析其有效性和安全性。方法 我们对国内外8个数据库进行了全面检索,检索时间截止为2023年5月,研究方法遵循Arksey和O’Malley提出的方法论框架,并对纳入研究的质量进行了严格评估。结果 从初筛出的8 207篇相关文献中最终纳入70篇文献,共涵盖8种联合治疗方案。67篇文献报告称,2种AHs联合治疗比单一用药更有效;3篇文献表明,2种AHs联合治疗比3种AHs联合治疗或单一用药更加有效和安全。33篇文献得出结论,2种AHs联合治疗比单一AHs治疗具有更好的安全性。此外,1篇文献发现,3种AHs联合治疗比单一治疗更有效,但它与更高的药物不良反应(ADR)发生率有关。结论 根据目前的研究证据,与单一治疗或3种AHs联合治疗AR相比,2种AHs的联合治疗已显示出优越的疗效和安全性。氮卓斯汀鼻喷剂联合地氯雷他定片是治疗AR最常见的治疗方案。
Objective To perform a scoping review to analyze the common treatment regimens of H_(1) antihistamines(AHs)combination therapy for allergic rhinitis(AR)and evaluate their efficacy and safety.Methods We conducted a comprehensive search of 8 databases from both China and abroad in May 2023,following the methodological framework proposed by Arksey and O’Malley.The quality of the included studies was rigorously evaluated.Results A total of 70 studies,covering 8 combination therapy regimens were included from 8207 related literatures.Sixty-seven studies reported that 2 AHs combination therapy was more effective than monotherapy,and 3 studies indicated that 2 AHs combination therapy was more effective and safer than 3 AHs combination therapy or monotherapy.Thirty-three studies concluded that 2 AHs combination therapy had a better safety profile than single AHs therapy.Additionally,1 study found that 3 AHs combination therapy was more effective than monotherapy,but it was associated with a higher incidence of adverse drug reactions(ADRs).Conclusion Based on the current evidence,2 AHs combination therapy has demonstrated superior efficacy and safety compared to monotherapy or 3 AHs combination therapy for AR.Specifically,the combination of Azelastine nasal spray and Desloratadine tablets has emerged as the most commonly utilized treatment regimen in the review.
作者
沈开丽
罗敏
董玄
张文志
唐富山
Shen Kaili;Luo Min;Dong Xuan;Zhang Wenzhi;Tang Fushan(Clinical Pharmacy Teaching and Research Office,School of Pharmacy,Zunyi Medical University,Zunyi Guizhou 563006,China;Department of Pharmacy,Affiliated Hospital of Zunyi Medical University,Zunyi Guizhou 563003,China)
出处
《遵义医科大学学报》
2024年第3期279-291,共13页
Journal of Zunyi Medical University
基金
贵州省中药民族药2011协同创新中心[NO:黔教技(2022)26]。
